ClinicalTrials.Veeva

Menu
C

California Retina Consultants | Bakersfield, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pegcetacoplan
Ranibizumab
KSI-301
UBX1325
APL-2
EYE103
Foselutoclax

Parent organization

This site is a part of California Retina Consultants

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 13 total trials

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy o...

Enrolling
Diabetic Macular Edema (DME)
Neovascular Age-related Macular Degeneration (NVAMD)
Drug: EYE103

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Enrolling
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection

Trial sponsors

Roche logo
AbbVie logo
A
Kodiak Sciences logo
U
E
Stealth BioTherapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems